Skip to main content
Top
Published in: BMC Primary Care 1/2011

Open Access 01-12-2011 | Study protocol

Effectiveness of regular reporting of spirometric results combined with a smoking cessation advice by a primary care physician on smoking quit rate in adult smokers: a randomized controlled trial. ESPIROTAB study

Authors: Mar Rodriguez-Alvarez, Pere Torán-Monserrat, Laura Muñoz-Ortiz, Antonio Negrete-Palma, Juan José Montero-Alia, Mercedes Jiménez-González, Elena Zurilla-Leonarte, Victoria Marina-Ortega, Montserrat Olle-Borque, Esther Valentin-Moya, Anna Cortada-Cabrera, Alexis Tena-Domingo, Silvia Martínez-González, Victoria Vila-Palau, Adriana Ramos-Ordoñez, Guida Rotllant-Estelrich, Carme Forcada-Vega, Eulàlia Borrell-Thió

Published in: BMC Primary Care | Issue 1/2011

Login to get access

Abstract

Background

Undiagnosed airflow limitation is common in the general population and is associated with impaired health and functional status. Smoking is the most important risk factor for this condition. Although primary care practitioners see most adult smokers, few currently have spirometers or regularly order spirometry tests in these patients. Brief medical advice has shown to be effective in modifying smoking habits in a large number of smokers but only a small proportion remain abstinent after one year. The aim of this study is to evaluate the effectiveness of regular reporting of spirometric results combined with a smoking cessation advice by a primary care physician on smoking quit rate in adult smokers.

Methods/design

Intervention study with a randomized two arms in 5 primary care centres. A total of 485 smokers over the age of 18 years consulting their primary care physician will be recruited.
On the selection visit all participants will undergo a spirometry, peak expiratory flow rate, test of smoking dependence, test of motivation for giving up smoking and a questionnaire on socio-demographic data. Thereafter an appointment will be made to give the participants brief structured advice to give up smoking combined with a detailed discussion on the results of the spirometry. After this, the patients will be randomised and given appointment for follow up visits at 3, 6, 12 and 24 months. Both arms will receive brief structured advice and a detailed discussion of the spirometry results at visit 0. The control group will only be given brief structured advice about giving up smoking on the follow up. Cessation of smoking will be tested with the carbon monoxide test.

Discussion

Early identification of functional pulmonary abnormalities in asymptomatic patients or in those with little respiratory symptomatology may provide "ideal educational opportunities". These opportunities may increase the success of efforts to give up smoking and may improve the opportunities of other preventive actions to minimise patient risk. Comparing adult smokers in the intervention group with those in the control group, a minimum improvement expected with respect to the rates of smoking cessation would represent a large number of avoided morbimortality.

Trial Registration

ClinicalTrials.gov: NCT01296295
Literature
1.
go back to reference Mathers CD: The global burden of disease: 2004 update. 2008, Geneva: World Health OrganizationCrossRef Mathers CD: The global burden of disease: 2004 update. 2008, Geneva: World Health OrganizationCrossRef
2.
go back to reference Mathers CD, Roncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLOS Medicine. 2006, 3: 2011-30.CrossRef Mathers CD, Roncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLOS Medicine. 2006, 3: 2011-30.CrossRef
3.
go back to reference Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet. 1997, 349: 1347-52. 10.1016/S0140-6736(96)07494-6.CrossRefPubMed Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet. 1997, 349: 1347-52. 10.1016/S0140-6736(96)07494-6.CrossRefPubMed
4.
go back to reference Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001, 163: 1256-76.CrossRefPubMed Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001, 163: 1256-76.CrossRefPubMed
5.
go back to reference Álvarez-Sala JL, Cimas E, Masa J, Miravitlles M, Molina J, Naberan K, Simonet P, Viejo J: Recommendations for the care of the patient with chronic obstructive pulmonary disease. Arch Bronconeumol. 2001, 37: 269-78.CrossRefPubMed Álvarez-Sala JL, Cimas E, Masa J, Miravitlles M, Molina J, Naberan K, Simonet P, Viejo J: Recommendations for the care of the patient with chronic obstructive pulmonary disease. Arch Bronconeumol. 2001, 37: 269-78.CrossRefPubMed
6.
go back to reference Sobradillo V, Miravitlles M, Jiménez CA, Gabriel R, Viejo JL, Masa JF, Fernández Fau L, Villasante C: Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol. 1999, 35: 159-66.CrossRefPubMed Sobradillo V, Miravitlles M, Jiménez CA, Gabriel R, Viejo JL, Masa JF, Fernández Fau L, Villasante C: Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol. 1999, 35: 159-66.CrossRefPubMed
7.
go back to reference Pacheco A: COPD: reflections on cause and course. Arch Bronconeumol. 2001, 37: 457-8.CrossRef Pacheco A: COPD: reflections on cause and course. Arch Bronconeumol. 2001, 37: 457-8.CrossRef
8.
go back to reference Sobradillo-Peña V, Miratvitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernández-Fau L: Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study. Chest. 2000, 118: 981-9. 10.1378/chest.118.4.981.CrossRef Sobradillo-Peña V, Miratvitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernández-Fau L: Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study. Chest. 2000, 118: 981-9. 10.1378/chest.118.4.981.CrossRef
9.
go back to reference Heffner JE: Chronic obstructive pulmonary disease: on an exponential curve of progress. Respir Care. 2002, 47: 586-607.PubMed Heffner JE: Chronic obstructive pulmonary disease: on an exponential curve of progress. Respir Care. 2002, 47: 586-607.PubMed
10.
go back to reference Miravitlles M, Soriano JB, García-Río F, Muñoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J: Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009, 64: 863-8. 10.1136/thx.2009.115725.CrossRefPubMed Miravitlles M, Soriano JB, García-Río F, Muñoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J: Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009, 64: 863-8. 10.1136/thx.2009.115725.CrossRefPubMed
11.
go back to reference Miravitlles M, Murio C, Guerreo T, Gisbert R, the DAFNE Study Group: Cost of Chronic Bronchitis and COPD. A 1-year follow-up study. Chest. 2003, 123: 784-91. 10.1378/chest.123.3.784.CrossRefPubMed Miravitlles M, Murio C, Guerreo T, Gisbert R, the DAFNE Study Group: Cost of Chronic Bronchitis and COPD. A 1-year follow-up study. Chest. 2003, 123: 784-91. 10.1378/chest.123.3.784.CrossRefPubMed
12.
go back to reference Siafakas NM, Tzortzaki EG: Few smokers develop COPD. Why?. Respir Med. 2002, 96: 615-24. 10.1053/rmed.2002.1318.CrossRefPubMed Siafakas NM, Tzortzaki EG: Few smokers develop COPD. Why?. Respir Med. 2002, 96: 615-24. 10.1053/rmed.2002.1318.CrossRefPubMed
13.
go back to reference Doherty DE: Early detection and management of COPD. What you can do to reduce the impact of this disabling disease. Postgrad Med. 2002, 111: 41-50.CrossRefPubMed Doherty DE: Early detection and management of COPD. What you can do to reduce the impact of this disabling disease. Postgrad Med. 2002, 111: 41-50.CrossRefPubMed
14.
go back to reference Van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling JG: Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002, 324: 1370-4. 10.1136/bmj.324.7350.1370.CrossRefPubMedPubMedCentral Van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling JG: Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002, 324: 1370-4. 10.1136/bmj.324.7350.1370.CrossRefPubMedPubMedCentral
15.
go back to reference Zieliñski J, Bednarek M, the Know the Age of Your Lung Study Group: Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001, 119: 731-36. 10.1378/chest.119.3.731.CrossRefPubMed Zieliñski J, Bednarek M, the Know the Age of Your Lung Study Group: Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001, 119: 731-36. 10.1378/chest.119.3.731.CrossRefPubMed
16.
go back to reference National Heart, Lung, and Blood Institute, Worl Health Organixation. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. 2001, National Institutes of Health (NIH) Publication N°. 2701A, [http://www.goldcopd.com] National Heart, Lung, and Blood Institute, Worl Health Organixation. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. 2001, National Institutes of Health (NIH) Publication N°. 2701A, [http://​www.​goldcopd.​com]
17.
go back to reference Generalitat de Catalunya. Departament de Sanitat i Seguretat Social: Pla de Salut de Catalunya 2002-2005. 2003, Barcelona: Departament de Sanitat i Seguretat Social Generalitat de Catalunya. Departament de Sanitat i Seguretat Social: Pla de Salut de Catalunya 2002-2005. 2003, Barcelona: Departament de Sanitat i Seguretat Social
19.
go back to reference Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, the Lung Health Study Research Group: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatador on the rate decline of FEV1. The Lung Health Study. JAMA. 1994, 272: 1497-1505. 10.1001/jama.272.19.1497.CrossRefPubMed Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, the Lung Health Study Research Group: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatador on the rate decline of FEV1. The Lung Health Study. JAMA. 1994, 272: 1497-1505. 10.1001/jama.272.19.1497.CrossRefPubMed
20.
go back to reference Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M: Smoking reduction, smoking cessation and mortality: a 16-year follow-up of 19732 men and women from the Copenhagen Cente for Prospective Population Studies. Am J Epidemiol. 2002, 156: 994-1001. 10.1093/aje/kwf150.CrossRefPubMed Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M: Smoking reduction, smoking cessation and mortality: a 16-year follow-up of 19732 men and women from the Copenhagen Cente for Prospective Population Studies. Am J Epidemiol. 2002, 156: 994-1001. 10.1093/aje/kwf150.CrossRefPubMed
21.
go back to reference Tonnensen P, Carrozzi L, Fargerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Resp J. 2007, 29: 390-417.CrossRef Tonnensen P, Carrozzi L, Fargerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Resp J. 2007, 29: 390-417.CrossRef
22.
go back to reference Jimenez Ruiz CA, Sobradillo Peña V, Miravitlles M, Gabriel R, Villasante C, Masa JF, Fernández Fau L, Viejo Bañuelos JL: Análisis de tabaquismo en España a la luz de los resultados del estudio IBERPOC. Prev Tab. 2000, 2: 189-193. Jimenez Ruiz CA, Sobradillo Peña V, Miravitlles M, Gabriel R, Villasante C, Masa JF, Fernández Fau L, Viejo Bañuelos JL: Análisis de tabaquismo en España a la luz de los resultados del estudio IBERPOC. Prev Tab. 2000, 2: 189-193.
23.
go back to reference Wagena EJ, Zeegers MPA, Van Schayck CP, Wouters EFM: Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf. 2003, 26: 381-403. 10.2165/00002018-200326060-00002.CrossRefPubMed Wagena EJ, Zeegers MPA, Van Schayck CP, Wouters EFM: Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf. 2003, 26: 381-403. 10.2165/00002018-200326060-00002.CrossRefPubMed
24.
go back to reference Solà-Morales O: The promotion of the tobacco abandonment: a revision of the strategies. Agència d'Avaluació de Tecnologia i Recerca Mèdiques. 2003 Solà-Morales O: The promotion of the tobacco abandonment: a revision of the strategies. Agència d'Avaluació de Tecnologia i Recerca Mèdiques. 2003
25.
go back to reference Lancaster T, Stead LF: Individual behavioral counseling for smoking cessation. Cochrane Database Syst Rev. 2002, 3: CD001292 Lancaster T, Stead LF: Individual behavioral counseling for smoking cessation. Cochrane Database Syst Rev. 2002, 3: CD001292
26.
go back to reference Law M, Tang JL: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Inter Med. 1995, 155: 1933-41. 10.1001/archinte.155.18.1933.CrossRef Law M, Tang JL: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Inter Med. 1995, 155: 1933-41. 10.1001/archinte.155.18.1933.CrossRef
27.
go back to reference Torrecilla M, Barrueco M, Maderuelo JA, Jiménez CA, Plaza MD, Hernández MA: Tobacco detoxication at a primary care clinic: efficacy of medical counselling, the minimal intervention and nicotine replacement therapy at one-year control. Aten Primaria. 2001, 27: 629-36.CrossRef Torrecilla M, Barrueco M, Maderuelo JA, Jiménez CA, Plaza MD, Hernández MA: Tobacco detoxication at a primary care clinic: efficacy of medical counselling, the minimal intervention and nicotine replacement therapy at one-year control. Aten Primaria. 2001, 27: 629-36.CrossRef
28.
go back to reference Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J: Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003, 123: 1916-23. 10.1378/chest.123.6.1916.CrossRefPubMed Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J: Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003, 123: 1916-23. 10.1378/chest.123.6.1916.CrossRefPubMed
29.
go back to reference Bize R, Burnand B, Mueller Y, Rège Walther M, Cornuz J: Biomedical risk assessment as an aid for smoking cessation. Cochrane Database of Systematic Reviews. 2009, Art. No.: CD004705, 2CrossRef Bize R, Burnand B, Mueller Y, Rège Walther M, Cornuz J: Biomedical risk assessment as an aid for smoking cessation. Cochrane Database of Systematic Reviews. 2009, Art. No.: CD004705, 2CrossRef
30.
go back to reference Parkes G, Griffin M, Dent R: Effect on smoking quit rate of telling patients their lung age: the Step 2 quit randomised controlled trial. BMJ. 2008, 336: 598-600. 10.1136/bmj.39503.582396.25.CrossRefPubMedPubMedCentral Parkes G, Griffin M, Dent R: Effect on smoking quit rate of telling patients their lung age: the Step 2 quit randomised controlled trial. BMJ. 2008, 336: 598-600. 10.1136/bmj.39503.582396.25.CrossRefPubMedPubMedCentral
31.
go back to reference Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM: Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007, 9 (1): 21-32. 10.1080/14622200601078509.CrossRefPubMed Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM: Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007, 9 (1): 21-32. 10.1080/14622200601078509.CrossRefPubMed
Metadata
Title
Effectiveness of regular reporting of spirometric results combined with a smoking cessation advice by a primary care physician on smoking quit rate in adult smokers: a randomized controlled trial. ESPIROTAB study
Authors
Mar Rodriguez-Alvarez
Pere Torán-Monserrat
Laura Muñoz-Ortiz
Antonio Negrete-Palma
Juan José Montero-Alia
Mercedes Jiménez-González
Elena Zurilla-Leonarte
Victoria Marina-Ortega
Montserrat Olle-Borque
Esther Valentin-Moya
Anna Cortada-Cabrera
Alexis Tena-Domingo
Silvia Martínez-González
Victoria Vila-Palau
Adriana Ramos-Ordoñez
Guida Rotllant-Estelrich
Carme Forcada-Vega
Eulàlia Borrell-Thió
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2011
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/1471-2296-12-61

Other articles of this Issue 1/2011

BMC Primary Care 1/2011 Go to the issue